Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
Cantor upgrades Omeros to Overweight with a $22 price forecast following strong Yartemlea sales and Medicare reimbursement momentum.
Share
Why It Matters
A smart investor thinks Omeros' transplant drug is selling really well. Watch if the company keeps growing sales and stays profitable over time.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.